Arca
Skip to content
Tools
Tools

ATP synthase

Complex in Mycobacterium tuberculosis that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1
  • Genes: 8

Who is on it, and how far along

Every drug ChEMBL records acting on ATPA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Bedaquiline

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        BedaquilineBoxed warningApprovedJohnson & JohnsonSmall moleculeInhibitorATP synthase inhibitor33

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in ChildrenBedaquilinePhase 2RecruitingHuashan HospitalOct 26, 2026
        A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant TuberculosisBedaquilinePhase 3Not yet recruitingSeoul National University HospitalJun 30, 2026
        Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary TuberculosisBedaquilinePhase 2RecruitingGates Medical Research InstituteApr 13, 2026
        Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)BedaquilinePhase 3RecruitingAssistance Publique - Hôpitaux de ParisMar 20, 2026
        Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform TrialBedaquilinePhase 2Not yet recruitingThe University of QueenslandMar 20, 2026
        Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BLMZ Chinese CohortBedaquilinePhase 3Not yet recruitingBeijing Chest HospitalDec 8, 2025
        Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary InfectionBedaquilinePhase 1Enrolling by invitationVancouver Coastal HealthNov 14, 2025
        BPaLMZ for TB MeningitisBedaquilinePhase 2RecruitingDavid BoulwareNov 13, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364166, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.